DERMATOLOGICAL SIDE EFFECTS OF CURRENT AND UPCOMING TARGETED THERAPIES IN ONCOLOGY

被引：7

作者：

Bonny, M. ^{[1
]}

Buyse, V ^{[2
]}

Brochez, L. ^{[1
]}

机构：

[1] Univ Hosp Ghent, Dept Dermatol, Ghent, Belgium

[2] OLV van Lourdes Hosp, Waregem, Belgium

来源：

ACTA CLINICA BELGICA | 2011年 / 66卷 / 02期

关键词：

Skin toxicity; targeted therapy; oncology; ORAL MEK INHIBITOR; RENAL-TRANSPLANT RECIPIENTS; PHASE-I; ADVANCED CANCERS; CELL LUNG; BEVACIZUMAB; MANAGEMENT; SIROLIMUS; ERUPTION; PD-0325901;

D O I：

10.2143/ACB.66.2.2062526

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Targeted therapies are gaining field in oncology practice. Some of them are already well established, others are upcoming. They target cancer cells more selectively, therefore causing less collateral damage. Dermatologic side effects are common and sometimes class specific. The skin toxicity profile of EGFR inhibitors, MEK en Raf inhibitors, mTOR inhibitors, VEGF targeting molecules, multikinase inhibitors, the HER2 monoclonal antibody trastuzumab and the CTLA-4 monoclonal antibodies are discussed. When possible, a pathogenic mechanism and treatment options are described.

引用

收藏

页码：97 / 103

页数：7

相关论文

共 39 条

[31] Hand eruption after intravenous administration of bevacizumab [J].

Ruiz, V. ;

Garcia-Muret, M. P. ;

Alomar, A. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2011, 25 (02) :238-239

[32] Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders [J].

Schad, Karin ;

Conzett, Katrin Baumann ;

Zipser, Marie C. ;

Enderlin, Valerie ;

Kamarashev, Jivko ;

French, Lars E. ;

Dummer, Reinhard .

CLINICAL CANCER RESEARCH, 2010, 16 (03) :1058-1064

[33] Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma [J].

Schmidinger, Manuela ;

Bellmunt, Joaquim .

CANCER TREATMENT REVIEWS, 2010, 36 (05) :416-424

[34] Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors [J].

Segaert, S ;

Van Cutsem, E .

ANNALS OF ONCOLOGY, 2005, 16 (09) :1425-1433

[35]

Segaert S, 2010, SKIN, V13, P168

[36] Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer [J].

Stone, Rebecca L. ;

Sood, Anil K. ;

Coleman, Robert L. .

LANCET ONCOLOGY, 2010, 11 (05) :465-475

[37] Evidence-Based Treatment Options for the Management of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors [J].

Tan, Eng Hooi ;

Chan, Alexandre .

ANNALS OF PHARMACOTHERAPY, 2009, 43 (10) :1658-1666

[38] Perforating dermatosis in a patient receiving bevacizumab [J].

Vano-Galvan, S. ;

Moreno, C. ;

Medina, J. ;

Perez-Garcia, B. ;

Garcia-Lopez, J. L. ;

Jaen, P. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (08) :972-974

[39] Cutaneous side effects of inhibition of VEGF signal transduction [J].

Wozel, Gottfried ;

Sticherling, Michael ;

Schoen, Michael P. .

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2010, 8 (04) :243-249

← 1 2 3 4 →